Progress towards a new targeted treatment approach that will provide personalised medicine, rather than providing the same first line treatment for conditions, will amass more patient data than ever before. Being able to handle and store this data, whilst ensuring it is readily available for other healthcare organisations, is essential.
Additionally, with the cost of drug development rising and existing drugs coming off patent at an alarming rate, high-performing pharmaceutical firms are focusing on data-driven approaches to dramatically improve efficiencies across manufacturing, distribution and markets, while gaining better insight to drive improved decision making. It is estimated that such efficiencies could save the industry as much as $90bn.
With sales fast increasing and Pharmaceutical organisations looking at new forms of marketing and customer retention, it is clear that a new solution is required to ensure compliance, security and the ability to implement a data-driven approach. Cloud environments can underpin the deployment of the digital technologies you need to support transformation, for example combatting existing issues surrounding drug prescriptions by pharmaceutical organisations and patients’ subsequent concerns around who has accessed their records. Similarly this could also enable pharmaceutical companies to develop a deeper insight and understanding of the NHS.
UKCloud Health offers a cost-effective cloud platform that represents genuine value-for-money, even when compared with global cloud platforms.
Digital readiness first requires a modern and resilient IT environment. UKCloud Health provides a safe and efficient foundation which is resilient against physical and cyber risks.
Our award-winning multi-cloud platform spans Crown Campus (government-grade UK datacentres), on-premises and hyperscale environments for maximum flexibility. It is natively connected to the Health and Social Care Network (HSCN) and is aligned with the Data Security & Protection (DSP) toolkit.
UKCloud Health uses a combination of familiar and proven technologies such as VMware, and so enables you to leverage your existing skills and tools.
Digital technology is able to drive significant efficiencies; from the automation of operational processes through to the effective sharing of accurate clinical data across organisations.
UKCloud Health powers a catalogue of specialised Software-as-a-Service solutions from Digital Care Records and Clinical Pathway Management Systems, to Medical Image Routing and Electronic Document Management. These will help you accelerate time-to-value, avoid the constraints of lack of skills/resources and reduce the risk of failed IT development projects.
Multi-cloud brings together the modernisation of existing applications, the integration of SaaS solutions and the ability to develop cloud native applications without compromising connectivity, assurance or control.
We believe an appropriately governed digital HealthTech ecosystem is the best way to achieve a digital-first future. Our secure and trusted multi-cloud platform provides the ideal environment for innovators to develop new capabilities based on technologies such as artificial intelligence, augmented reality and internet of things.
UKCloud Health enforces standards, regulations and interoperability, so that you can focus on genuinely transforming patient experience and improving their outcomes.
Working together; our people, partners and platform are able to make your digital transformation happen – cheaper, faster and safer
$92bn worth of name-brand drugs will come off patent in the next five years. In an industry already challenged by over-capacity, there will be greater emphasis than ever on manufacturing efficiency.
From component sourcing and resource planning to capacity planning and production a data-driven approach to improving efficiency is essential to retaining competitive advantage.
87% of prescription drug sales were handled by distributors in 2010, a 6% increase over 2007.
Shortening the supply chain and generating greater efficiencies from closer integration and collaboration present not only a great challenge, but also an enormous opportunity.
In the last year alone the top 3 pharmaceutical giants incurred $7bn in additional costs settling fines for illegal marketing.
A new data-driven approach is required to improve targeting, avoid infringements and improve overall efficiency.